Rubicon Research将于10月9日公布, 通过IPO募集1,377.51,377.5, 股价为461-485461-485。 Rubicon Research to go public on Oct. 9, raising ₹1,377.5 crore via IPO with shares priced at ₹461–485.

2025年10月9日, 制药公司Rubicon Research推出IPO, Pharmaceutical company Rubicon Research is launching an IPO on October 9, 2025, aiming to raise ₹1,377.5 crore through a fresh issue of ₹500 crore and an offer-for-sale of ₹877.5 crore. 价格范围为每股461到485美元,订阅时间为10月13日. The price band is ₹461 to ₹485 per share, with subscriptions open until October 13. 收益将为债务偿还、收购和一般公司需求提供资金。 Proceeds will fund debt repayment, acquisitions, and general corporate needs. 大西洋总促进者将保留52.15%的股份。 Promoter General Atlantic will retain a 52.15% stake post-IPO. 该公司的重点是供受管制市场使用的特种药品和药品制造产品,经营林业发展局在印度检查的设施,最近还收购了Alkem Laboratories的Pithampur工厂。 The company, focused on specialty pharmaceuticals and drug-device products for regulated markets, operates FDA-inspected facilities in India and recently acquired Alkem Laboratories’ Pithampur plant. IPO拨款的75%分配给机构买家,15%分配给非机构投资者,10%分配给零售投资者,并定于10月16日列入名单。 The IPO allocation is 75% to institutional buyers, 15% to non-institutional investors, and 10% to retail investors, with listing scheduled for October 16.